Sorivudine topical

Drug Profile

Sorivudine topical

Alternative Names: ARYS-01; JA-001

Latest Information Update: 27 May 2015

Price : $50

At a glance

  • Originator aRigen
  • Class Antivirals; Nucleosides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Herpes zoster

Most Recent Events

  • 22 May 2009 Sorivudine topical is no longer licensed to Janus Pharmaceuticals (now Topica Pharmaceuticals) in USA
  • 20 Feb 2007 Interim results from a phase II trial in patients with Herpes zoster added to the adverse events and Viral Infections therapeutic trials sections
  • 07 Dec 2006 Final results from a phase II clinical trial (ARYS-0502) for Herpes zoster added to the Viral Infections therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top